HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 12/14/2012 -- J.C. Penney (NYSE:JCP) is undergoing some major changes in an effort to transform its stores and turn things around. The main idea is to de-clutter the stores and focus on shops (stores within the store) to make customers more comfortable while shopping and try to keep them in the stores as much as possible. When focusing on the customer experience, they will be engaging customers in a nice environment that can’t be found anywhere else. First, by cleaning the stores (less merchandise), they are assuring that the customers will have a better impression of the store. Based on personal experience I'd much rather be shopping in a place where I can easily find and appreciate what’s on display than having to go through endless racks of merchandise poorly classified.
Has JCP Found The Bottom and Breaks Its Previous High? Find Out Here
ArQule, Inc. (NASDAQ:ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 087, an orally bioavailable, potent multi-kinase inhibitor with pan-FGFR (fibroblast growth factor receptor) activity. The primary objective of the Phase 1 trial with ARQ 087 is determine its safety, tolerability and recommended Phase 2 dose. Patients with metastatic solid tumors who are refractory to available therapies or for whom no standard systemic therapy exists will be enrolled. The number of patients expected to be enrolled will depend on the number of patient cohorts investigated until dose-limiting toxicity is reached.
Should Investors Buy ARQL Now? Get Our Free Trend Analysis Here
MGIC Investment Corporation (NYSE:MTG) today issued an Operational Summary of its insurance subsidiaries for the month of November 2012 for their primary mortgage insurance. The information concerning new notices and cures is compiled from reports received from loan servicers. The level of new notice and cure activity reported in a particular month can be influenced by, among other things, the date on which a servicer generates its report, the number of business days in a month, and by transfers of servicing between loan servicers.
Get Free Trend Analysis On MTG: Just Free Sign Up Here
Celsion Corp. (NASDAQ:CLSN) CLSN +5.75% , looking back long-term on a monthly chart, has built a massive six-year base. It has recently edged above the resistance line of that channel and looks poised to move higher. Short-term, it has had a 5-wave move, and then spent about two weeks consolidating before it popped out of the wedge on Tuesday. On Wednesday it followed through a little bit to $8.83, reaching my target of $8.75 near the top of the channel before backing off a bit, only closing up 8 cents on the session. Nonetheless, it traded 3.2 million shares, and if it does continue up the rising channel, it could reach 11 or 12 shortly.
Should Investor Invest Money On CLSN At This Level: CLICK HERE To Know More
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)